Your Solutions
BIOMEDTRACKER
Real-time Event Tracking & Drug Development Analysis
管線研發追蹤、獲批前景分析、商業資訊、調研報告
DATAMONITOR HEALTHCARE
Disease Competitive Analysis, 10-20 Years Market Forecast, KOL Insights
疾病競爭分析、10-20年市場預測、KOL專訪
Meet the team
Julie Guan (China)
Head of Strategic Accounts
Citeline
Youmin Zhu (China)
Client Success Manager
Citeline
Training & Help
We provide product training support via online sessions/pre-recorded materials, please click below to access relevant contents, or reach out to this email for any customized training request: [email protected]
我們提供各產品的使用培訓支持，請點擊下列查閲相關培訓資源，若有特定培訓需求或安排則可聯絡：[email protected]
For access or technical issues, please contact your dedicated support team via 'Meet the Team', or contact Client Service team via below email:
若有任何登錄問題，請切換至Meet the Team版面並聯絡對接服務團隊，或可聯絡全球/亞太客服團隊：
Global - [email protected] (English only)
APAC - [email protected] (via English/Chinese)
Require Research Support?
Ask-the-Analyst™
Ask-the-Analyst™
Your status as a loyalty partner includes unlimited access to our highly acclaimed Ask-the-Analyst™ service. With a 24-hour response time, Ask-the-Analyst offers you authoritative information to help you make faster, smarter business decisions.
作爲重點合作夥伴，貴司用戶均可無限量使用「Ask-the-Analyst™」分析師咨詢服務。分析師團隊將會在24小時内回復（工作日），并爲您提供信息收集或專業見解，最終助您做出更快、更明智的業務決策。
Our Ask-the-Analyst team of industry experts leverages the complete suite of pharma intelligence products and publicly available sources to bring you the answers you’re looking for, while your information and all questions received are strictly confidential.
由業界專家組成的Ask the Analyst團隊將結合内部數據與公開領域資源爲您提供相關信息支持，您的個人資訊與提問内容均會被嚴格保密。
Latest Monthly Newsletter
Edition: August 2025
NEWS & INSIGHTS (incl. Key Themes, Latest Interviews, Recent Reg. Guidance)
- Notable Theme (Commercial): The seemingly insatiable appetite for drugs to treat metabolic diseases, which has seen China emerge as a key source of new R&D candidates, looks set to propel Eli Lilly and Novo Nordisk to become the world's largest pharma companies within the next five years.
- Notable Theme (Commercial): Japan continued to cut drug reimbursement prices via multiple mechanisms, including cost-effectiveness assessments for selected products, which most recently will lead to a 15% price cut for Alzheimer's therapy Leqembi.
- Notable Theme (Regulatory): European Medicines Agency's attempt to adopt a US-style "assessment aid" approach, where sponsors pre-fill regulatory templates, has not delivered the expected benefits in the EU.
EDITORIAL CONTENTS (incl. Podcasts, Webinars)
- Notable Podcast: Drug Fix: US FDA Changes COVID-19 Vaccine Labeling, Reimbursement Confusion Rises
- Notable Webinar: AI Won’t Replace You—But Clinical Teams Using It Might (September 24, 2025)
- Notable Webinar: How is China Shaping the Face of the Pharma Industry? (September 30, 2025)
DEALS & FINANCING (incl. M&As, Licensing, Financing)
- Notable M&A: Terumo to Pay $1.5B to Buy OrganOx
- Notable Licensing: BioArctic and Novartis Sign an Option, Collaboration and License Agreement using BrainTransporter Technology totalling $2B
- Notable Financing: Strand Therapeutics Gets $153M in Series B Financing
KEY R&D EVENTS (incl. Top-line Readouts, Analyst Commentary, Approval/CRL)
- Notable Analysis: IO Biotech | Cylembio | Melanoma (Phase 3): “Despite missing PFS mark, Cylembio combination shows clinical benefits over Keytruda alone in frontline metastatic melanoma…”
- Notable Analysis: Pfizer | Inclacumab | Sickle Cell Disease (Phase 3): “Pfizer’s inclacumab becomes second monoclonal antibody targeting P-selectin to fail Phase III trial in SCD…”
- Notable Analysis: Regeneron | Cemdisiran | Myasthenia Gravis (Phase 3): “Cemdisiran, an RNA interference therapy, emerges as a low-burden C5 inhibitor with competitive efficacy in gMG…”
RESEARCH REPORTS (incl. Forecast, Thought Leadership, KOL Interview)
- Notable Report: Commercialization Countdown: Step-by-Step Instructions for Acing Your Product Launch
- Notable Report: Q2 Round Up: You Can’t Always Get What You Want
- Notable Report: Gene, Cell, & RNA Therapy Landscape Q2 2025
- Notable Report: Disease Analysis: Pancreatic Cancer
- Notable Report: Disease Analysis: Sickle Cell Disease
- Notable Report: Patient-based Forecast: Chronic Urticaria
- Notable Report: Robotic-Assisted Surgical Systems
- Notable Report: Anemia of CKD KOL Interview - US, Northeast #1
- Notable Report: Diabetic Nephropathy (DN) KOL Interview - UK
- Notable Report: Pancreatic Cancer KOL Interview - US, East
Latest Editorial Podcasts
